Body mass index is closely correlated to incident diabetes in patients with heart failure or myocardial infarction

Background: Diabetes in patients with heart failure or myocardial infarction (MI) increases morbidity and mortality, but little is known about the impact of obesity on the risk of developing diabetes in these populations. Design: A cohort of patients consecutively hospitalized with heart failure (n = 3472) or MI (n = 5723) was followed in the period 1995–2006. Methods: Multivariable Cox proportional-hazard models were used to estimate the risk of developing diabetes according to the World Health Organization body mass index (BMI) classification. Normal weight patients (BMI 18.5–24.9 kg/m2) were used as the reference. Results: In both populations, more than half of the patients with a BMI above 34.9 kg/m2 developed diabetes. In heart failure patients, a BMI above 24.9 kg/m2 was associated with an increased risk of diabetes for the three BMI groups, i.e. 25.0–29.9 kg/m2, 30.9–34.9 kg/m2, and >34.9 kg/m2, with adjusted hazard ratios (HRs) of 2.16 (95% confidence interval 1.50–3.12), 3.89 (2.61–5.78), and 6.06 (3.79–9.69), respectively. In MI patients, the adjusted HRs in the three corresponding BMI groups were 1.84 (1.44–2.37), 4.31 (3.26–5.69), and 9.50 (6.70–13.46), respectively. Incident diabetes was associated with increased cardiovascular and all-cause mortality risks with adjusted HRs of greater magnitude than in prevalent diabetes. Conclusion: BMI was an independent predictor of incident diabetes in patients with either heart failure or MI. More than half of the patients with a BMI above 34.9 kg/m2 developed diabetes during follow-up. Incident diabetes carries an increased mortality risk.

[1]  C. Torp‐Pedersen,et al.  Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. , 2004, Journal of the American College of Cardiology.

[2]  S. Solomon,et al.  Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction: The Valsartan in Acute Myocardial Infarction (VALIANT) Trial , 2004, Circulation.

[3]  V. Gudnason,et al.  Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavik Study , 2005, European Journal of Cardiovascular Prevention & Rehabilitation.

[4]  P. Poole‐Wilson,et al.  Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET) , 2007, Heart.

[5]  S. Ball,et al.  The incomplete Bucindolol Evaluation in Acute myocardial infarction Trial (BEAT) , 2002, European journal of heart failure.

[6]  Matteo Anselmino,et al.  Diabetes, prediabetes and cardiovascular risk , 2010, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[7]  D. Tanné,et al.  Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. , 2005, European heart journal.

[8]  G. Fonarow,et al.  Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. , 2010, Journal of the American College of Cardiology.

[9]  L. Køber,et al.  Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimen. The TRACE Study Group. , 2000, European heart journal.

[10]  A. Ahlbom,et al.  Primary risk factors influence risk of recurrent myocardial infarction/death from coronary heart disease: results from the Stockholm Heart Epidemiology Program (SHEEP) , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[11]  M. Osler,et al.  The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. , 2003, Journal of clinical epidemiology.

[12]  A. Vaag,et al.  Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk: A Population Study of 3.3 Million People , 2008, Circulation.

[13]  L. Køber,et al.  Impact of obesity as a mortality predictor in high-risk patients with myocardial infarction or chronic heart failure: a pooled analysis of five registries. , 2008, European heart journal.

[14]  K. Dickstein,et al.  A randomised trial of a pre‐synaptic stimulator of DA2‐dopaminergic and α2‐adrenergic receptors on morbidity and mortality in patients with heart failure , 2008, European journal of heart failure.

[15]  P. Andersen,et al.  Rapid estimation of left ventricular ejection fraction in acute myocardial infarction by echocardiographic wall motion analysis. , 1992, Cardiology.

[16]  Hirofumi Makino,et al.  Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  M. Mosller Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: Rationale, design, and patient characteristics of the DIAMOND studies , 1997, Clinical cardiology.